TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 years and over at the time of consent to the study.~* Diagnosis of SpA, as defined by the ASAS criteria for axial SpA~* Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of \> 1 month (for both NSAIDs combined) before the Screening visit.~* Active axial involvement defined by mini BASDAI~Exclusion Criteria:~* Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.~* Subjects who have received any previous treatment with etanercept or other TNFα inhibitors or biologic agents.~* Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: ACTIVE_COMPARATOR): Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
- etanercept-placebo (Type: PLACEBO_COMPARATOR): Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1.Patients 18 years of age or older with a new or existing diagnosis of cancer with a CVC inserted within the last 72 hours.~Exclusion Criteria:~1. CVC in place for \>72 hours~2. Patient requires anticoagulation for other indication~3. Concomitant use of dual antiplatelet therapy~4. Prior VTE~5. Major bleeding event in the last 6 weeks~6. Patient on concomitant medication with known interaction with rivaroxaban (eg. CYP3A4 inhibitor)~7. Pregnancy (documentation of use of effective contraception if sexually active or negative B-Hcg required)~8. Known renal failure, based on Creatinine clearance \<30 mL/min (Cockcroft-Gault) (in the previous 3 months)~9. Documented severe liver disease (eg. acute clinical hepatitis, chronic active hepatitis, cirrhosis or ALT \>3ULN) ( in the previous 3 months)~10. Known thrombocytopenia \< 50x 109/L (in the previous 3 months)~11. Allergy to rivaroxaban~12. Life expectancy \<6 months~13. History of condition at increased bleeding risk including, but not limited to:~    1. Major surgical procedure or trauma within 30 days before the randomization visit~   2. Clinically significant gastrointestinal bleeding within 6 months before the randomization visit~   3. History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding~   4. Chronic hemorrhagic disorder~   5. Known intracranial neoplasm, arteriovenous malformation, or aneurysm~   6. Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg~14. Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or myelodysplastic syndrome~15. Geographic inaccessibility~16. Refused or unable to obtain consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban Thromboprophylaxis (Type: EXPERIMENTAL): Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
- Standard of care (Type: NO_INTERVENTION): No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of RA, axSpA, PsA or PsO~* No prior treatment with etanercept and eligibility for treatment with etanercept according to the summary of product characteristics.~Exclusion Criteria:~* The contraindications, special warnings, and precautions according to the summary of product characteristics for etanercept shall apply.~* The additional documentation of the patient in another post-marketing study with etanercept is not permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation Group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients with atrial fibrillation or flutter~* Age 18-84 years~* Willingness to participate in the study and ability to sign informed consent.~Exclusion Criteria:~* Atrial fibrillation due to a reversible cause~* moderate or severe mitral stenosis~* conditions other than atrial fibrillation that require anticoagulation (e.g., a prosthetic heart valve)~* A need for aspirin at a dose of \>165 mg a day or for both aspirin and P2Y-inhibitor~* Serious bleeding event in the previous 6 months or a high risk of bleeding (eg, active peptic ulcer disease)~* a platelet count of \<100,000/mm3 or hemoglobin level of \<10 g/dL~* stroke within the previous 10 days~* documented hemorrhagic tendencies, or blood dyscrasias~* Renal insufficiency (serum creatinine level of 12.5 mg per deciliter or calculated creatinine clearance of \<50 ml per minute)~* Weight in excess of 325 pounds~* Resting hypotension (systolic blood pressure of \<90mmHg) or resting hypertension (systolic blood pressure of \>170mmHg or diastolic blood pressure of \>110 mmHg)~* History of active malignancy requiring concurrent chemotherapy~* Known allergy to iodinated contrast material~* pregnancy, women of childbearing potential unwilling to use adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- apixaban (Type: ACTIVE_COMPARATOR): apixaban 5 mg or 2.5 mg po bid
- warfarin (Type: PLACEBO_COMPARATOR): warfarin with target INR of 2-3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Experience of Thalidomide in Thalassemic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical and genetic diagnosis of β-thalassemia major and intermedia~2. Patients who showed partial response or a decline in response to hydroxyurea~3. Patients who are not the candidates for the bone marrow transplant procedure.~Exclusion Criteria:~1. Married Patients~2. Patients with comorbidities such as liver, cerebrovascular, cardiovascular, or kidney diseases~3. Patients allergic to the drug ingredients~4. Patients with mental disorders~5. Patients who are enrolled in other clinical trials~6. Patients with a history of venous or arterial thrombosis

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of hydroxyurea and thalidomide (Type: EXPERIMENTAL): Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Posttraumatic Stress Disorder, chronic, related to World Trade Center Attacks~* Age 18-70~* CAPS score greater than 45~* Willingness to consent~* For women, negative pregnancy test and using adequate birth control~Exclusion Criteria:~* Prominent suicidal ideation~* Current psychotic disorder~* Unstable medical illness~* Women who are pregnant or nursing mothers~* Alcohol or substance use disorder in the past 3 months~* History of seizure disorder~* conditions that contraindicate use of paroxetine~* inability to tolerate a drug free period prior to beginning the study of 4 weeks for MAOIs or fluoxetine and 2 weeks for other psychotropic drugs, except zolpidem for insomnia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Paroxetine (Type: EXPERIMENTAL): Paroxetine and Prolonged Exposure Therapy
- Placebo pill (Type: PLACEBO_COMPARATOR): Placebo pill plus Prolonged Exposure Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least 18 years of age.~* Subjects who are candidates for routine, uncomplicated cataract surgery.~* Subjects who, in the Investigator's opinion, have potential postoperative pinholed Snellen visual acuity (VA) of at least 20/200 in the study eye.~Exclusion Criteria:~* Subjects who have known hypersensitivity or contraindication to the study drug or components.~* Subjects with a severe/serious ocular condition, or any other unstable medical condition, that in the investigator's opinion may preclude study treatment or follow-up.~* Subjects with elevated intraocular pressure (\>/= 21mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye.~* Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol Etabonate (Type: EXPERIMENTAL): Loteprednol etabonate
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle of loteprednol etabonate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AZD0585 Phase III Long-term Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Japanese men or women, ≥20 years of age.~* Subjects must meet all of the following criteria;~  1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 - 499 mg/dL~ 2. %TG change between Visit 2 and Visit 3 must be within 30%~ 3. %LDL-C change between Visit 2 and Visit 3 must be within 25%~Key Exclusion Criteria:~* Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.~* Known lipoprotein lipase impairment or deficiency, or Apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.~* Current or history of pancreatitis.~* Type I diabetes mellitus, use of insulin, or haemoglobin A1c \>10% at Visit 1.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- AZD0585 2g group (Type: EXPERIMENTAL): AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
- AZD0585 4g group (Type: EXPERIMENTAL): AZD0585 1g × 4 capsules once daily
- Placebo control group (Type: PLACEBO_COMPARATOR): AZD0585 placebo 1g × 4 capsules once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heterologous Boost Immunization With an Aerosolised Ad5-nCoV After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Health subjects aged ≥18 years.~* Have received two-dose inactivated SARS-CoV-2 vaccine before 6 months or more.~* The subject can provide with informed consent and sign informed consent form (ICF).~* The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study.~Exclusion Criteria:~* Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.~* Be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination.~* Women with positive urine pregnancy test.~* Have acute febrile diseases and infectious diseases.~* Axillary temperature\>37.0℃.~* Have serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by medication (systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg when measured in the field).~* Have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease.~* Congenital or acquired angioedema / neuroedema.~* Have the history of urticaria 1 year before receiving the investigational vaccine.~* Have asplenia or functional asplenia.~* Patients with chronic obstructive pulmonary disease, pulmonary fibrosis and other pulmonary abnormalities.~* Have history of SARS-CoV-2 infection or COVID-19.~* Have symptoms of upper respiratory tract infection.~* Have traveled to medium or high risk areas or traveled abroad in the past 21 days, and epidemiologically contacted with SARS-CoV-2.~* Any medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
- Group B (Type: EXPERIMENTAL): Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
- Group C (Type: EXPERIMENTAL): Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients included in this study must be over 18 years with good general and oral health~* Free teeth having carious lesions and periodontal disease agree with the informed consent document~* The color of the upper anterior teeth is classified as A2 or greater value, according to the scale VITA Classical (Vita Zahnfabrik, Bad Sackingen, Germany) and the spectrophotometer Easyshade Vita (Vita Zahnfabrik, Bad Sackingen, Germany).~Exclusion Criteria:~* Have already made treatment tooth whitening~* Dental prosthesis having options at the upper front teeth~* Who are pregnant or lactating~* Presenting gingival recession~* Tooth sensitivity~* Endodontic treatment in anterior maxillary teeth~* Which have a severe internal coloring~* Cervical lesions carious~* Taking medications (AINES)~* Fixed orthodontic appliances~* Submit bruxism habits~* Having visible cracks in teeth~* Those who are not available to attend the controls.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- healthy patients bleaching (Type: ACTIVE_COMPARATOR): Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
- Smokers bleaching (Type: EXPERIMENTAL): smokers patients Peroxide Carbamide 10% - Dental bleaching treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 diabetes~* Patients should be drug naïve ie, not received medical treatment for diabetes,~* HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)~Exclusion Criteria:~* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes),~* Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* cutaneous malignant melanoma;~* advanced, inoperable stage IV melanoma;~* measurable and/or evaluable sites of metastases.~Exclusion Criteria:~* prior chemotherapy and/or IFN/IL2 based immunotherapy for metastatic disease;~* prior malignancies within past 5 years, with the exception of cured non-melanoma skin cancer, or in situ cancer of cervix;~* clinically significant cardiovascular disease;~* ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hormone-receptor positive early breast cancer~* Menopausal status~* Age \< 75 years~* Written informed consent~Exclusion Criteria:~* Premenopausal status at time of randomization~* Comorbidities with increased risk of osteoporosis (primary hyperparathyroidism, hyperthyroidism, rheumatoid arthritis)~* BMI \< 18~* Chronic use of steroids~* Use of bisphosphonates at time of randomization~* Psychiatric disorders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Ibandronic acid (Type: EXPERIMENTAL): Ibandronic acid 150 mg per os per month for two years
- Arm B: Placebo (Type: PLACEBO_COMPARATOR): Placebo per os per month for two years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete